Team:KAIST-Korea/FutureWorks

From 2010.igem.org

(Difference between revisions)
(Disadvantage of All-in-One)
(Disadvantage of All-in-One Implementation)
Line 17: Line 17:
== Disadvantage of '''All-in-One''' Implementation ==
== Disadvantage of '''All-in-One''' Implementation ==
-
So we tried to selectively express modified antigen receptor genes.
+
So we tried to selectively express modified antigen receptor genes to use promoter with different activator molecule. With this '''All-in-One''' implementation, one yeast cell have genes for GFP with GAS element, STAT1 signal transduction molecule and every modified antigen receptor with promoters whose activator is different. In theoretically, this implementation solve the problem of '''cross-talking''' of modified antigen receptors. But this implementation have two problems.
 +
# Though we don't activate the promoter, yeast cell express the gene naturally. Therefore, we can't solve the problem of '''cross-talk''' perfectly.
 +
# We need to assign promoters with different activator for each modified antigen receptors. But the number of disease is more than the number of promoters with different activator obviously.
== Our Final Solution ==
== Our Final Solution ==

Revision as of 10:57, 27 October 2010

 

Future Works




Our final goal is to develop the universal diagnosis kit. But if we express more than one modified antigen receptor, signal from these receptors will be cross-talked. To prevent this crosstalk, we decided to selectively express specific modified receptor. Our first plan was to embed all gene of modified antigen receptors with promoter whose activators are different. But these idea have some problems. First of all, though we don't activate genes, there are expressions of genes. It is not possible to suppress gene 100%. So we planned to use the 'conjugation' of Schizosaccharomyces pombe. So we will make 'antigen-binding' yeasts of different antigens and 'signal-transduction' yeast separately. And the diagnostician conjugate 'antigen-binding' yeast of certain antigen and common 'signal transduction' yeast before the diagnosis.

Contents

Our Final Goal and Problem of Cross-talking implementation

Our final goal is to develop the universal diagnosis kit for every disease whose antibody is produced. To perform this goal, the yeast should express modified antigen receptor of wanted disease, STAT1 proteins and have GFP gene whose promoter have GAS element. Most easiest way to way to detect existence of antigen is to express every antigen receptor on one yeast cell and integrate these signal into GFP with common STAT1 dimerization pathway. But this way have problems. Though the GFP is expressed, we can't sure which antigen is detected, because any antigen binding can turn on the GFP expression. Therefore, the cross-talking implementation can't be used for differential diagnosis because it can't eliminate any disease which can turn on the GFP expression.

Disadvantage of All-in-One Implementation

So we tried to selectively express modified antigen receptor genes to use promoter with different activator molecule. With this All-in-One implementation, one yeast cell have genes for GFP with GAS element, STAT1 signal transduction molecule and every modified antigen receptor with promoters whose activator is different. In theoretically, this implementation solve the problem of cross-talking of modified antigen receptors. But this implementation have two problems.

  1. Though we don't activate the promoter, yeast cell express the gene naturally. Therefore, we can't solve the problem of cross-talk perfectly.
  2. We need to assign promoters with different activator for each modified antigen receptors. But the number of disease is more than the number of promoters with different activator obviously.

Our Final Solution

Life Cycle of S.pombe

LifeCycleOfSpombe.jpg

How to implement?